It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dampen the immune process, while promoting beta cell survival and function. Liver receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1 agonism favors a dialogue between immune and islet cells, which could be druggable to protect against diabetes mellitus.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Hmadcha, Abdelkrim 10
; Florido, Javier P 11 ; Toscano, Miguel G 12 ; de Haan, Peter 12 ; Schoonjans, Kristina 13 ; Luis Sánchez Palazón 14 ; Marchetti, Piero 6 ; Schirmbeck, Reinhold 4 ; Martín-Montalvo, Alejandro 1 ; Meda, Paolo 15 ; Soria, Bernat 10 ; Bermúdez-Silva, Francisco-Javier 2
; St-Onge, Luc 16 ; Gauthier, Benoit R 1
1 Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
2 Unidad de Gestión Clínica Intercentros de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
3 Neurix SA, Geneva, Switzerland
4 Ulm University Hospital, Ulm, Germany
5 Facultad de Ciencias de la Salud, Universidad de Burgos, Burgos, Spain
6 Department Clinical and Experimental Medicine, University of Pisa—AOUP University Hospital, Pisa, Italy
7 Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy
8 Cell Isolation and Transplantation Centre, University Hospital, Geneva, Switzerland
9 Department of Cell Dynamics and Signalling, CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine, Seville, Spain
10 Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
11 Clinical Bioinformatics Area, Fundación Progreso y Salud, Consejería de Salud, Seville, Spain
12 Amarna Therapeutics, Seville, Spain
13 Laboratory of Metabolic Signaling, EPFL, Lausanne, Switzerland
14 Biological Resources, CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine, Seville, Spain
15 Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland
16 Munich, Germany




